Immunome (IMNM) Total Current Liabilities (2019 - 2026)
Immunome's (IMNM) quarterly Total Current Liabilities came in at $27.4 million in Q1 2026, down 10.99% YoY from $30.8 million in Q1 2025, and down 39.07% on a QoQ basis from $45.0 million in Q4 2025.
Immunome (IMNM) Total Current Liabilities (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Total Current Liabilities data on file, last reported at $27.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 10.99% year-over-year to $27.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.4 million (down 10.99% YoY) and the FY2025 annual result came in at $45.0 million, down 17.16% from the prior year.
- Total Current Liabilities eased to $27.4 million in Q1 2026, from $45.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $54.3 million in Q4 2024 to a low of $7.3 million in Q4 2022.
- A 5-year average of $26.5 million and a median of $26.4 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 213.62% — and 2025, when it plunged 42.66%.
- Tracing IMNM's Total Current Liabilities over 5 years: stood at $7.3 million in 2022, then soared by 197.76% to $21.8 million in 2023, then surged by 148.78% to $54.3 million in 2024, then declined by 17.16% to $45.0 million in 2025, then plunged by 39.07% to $27.4 million in 2026.
- The last three Total Current Liabilities figures came in at $27.4 million (Q1 2026), $45.0 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 35.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.71 Mn |
| Mar 31, 2026 | 27.41 Mn |
| Dec 31, 2025 | 44.99 Mn |
| Sep 30, 2025 | 31.45 Mn |
| Jun 30, 2025 | 22.88 Mn |
| Mar 31, 2025 | 30.80 Mn |
| Dec 31, 2024 | 54.31 Mn |
| Sep 30, 2024 | 39.53 Mn |
| Jun 30, 2024 | 39.90 Mn |
| Mar 31, 2024 | 30.77 Mn |
| Dec 31, 2023 | 21.83 Mn |
| Sep 30, 2023 | 23.11 Mn |
| Jun 30, 2023 | 26.39 Mn |
| Mar 31, 2023 | 24.83 Mn |
| Dec 31, 2022 | 7.33 Mn |
| Sep 30, 2022 | 7.37 Mn |
| Jun 30, 2022 | 8.62 Mn |
| Mar 31, 2022 | 9.71 Mn |
| Dec 31, 2021 | 9.73 Mn |
| Sep 30, 2021 | 7.77 Mn |